Drugs / Shuxuetong
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04946474 | Jun 2019 → Jul 2020 | intracerebral hemorrhage | Peking University Third Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03090113 | May 2017 → Mar 2019 | ischemic stroke | Beijing Tiantan Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Shuxuetong | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03090113 ↗ |
| Known as | Shuxuetong Injection | “The Shuxuetong injection, a purified extract of traditional Chinese medicine widely used for thrombus diseases in clinical practice in China, could be a promising agent to...” PMID 32994371 ↗ Feb 2020 |
| Modality | Traditional medicine (herbal / TCM) | “The Shuxuetong injection, a purified extract of traditional Chinese medicine widely used for thrombus diseases in clinical practice in China, could be a promising agent to...” PMID 32994371 ↗ Feb 2020 |
| Route | Oral | “Xingnaojing injection + Shuxuetong oral liquid” NCT04946474 ↗ |